Aortic and Heart Assist Procedures DRG 268 Reimbursement

DRG 268 includes inpatient aortic and heart assist device procedures except intra-aortic balloon pump when a Major Complication or Comorbidity is present, encompassing complex mechanical circulatory support interventions. This Diagnosis-Related Group is important for inpatient reimbursement because the Major Complication or Comorbidity designation reflects increased resource intensity and affects Medicare Severity Diagnosis-Related Group payment assignment.

DRG 268 Overview

DRG 268 covers inpatient cases involving aortic and heart assist device procedures, excluding intra-aortic balloon pump, in which a Major Complication or Comorbidity is present. These encounters typically involve high-resource cardiac surgical support such as ventricular assist devices or extracorporeal circulatory support and are among the more complex cardiovascular procedural groups. This Diagnosis-Related Group matters for Medicare payment because the presence of a Major Complication or Comorbidity increases relative resource use and impacts reimbursement classification under Medicare Severity Diagnosis-Related Group methodology. Accurate clinical coding and documentation of device procedures and associated complications are essential to classify cases into this Diagnosis-Related Group.

Acute mechanical circulatory support device trials: randomized or prospective comparative studies evaluating short-term outcomes of different temporary left ventricular assist devices, extracorporeal membrane oxygenation (ECMO) strategies, or intra-aortic balloon alternatives in patients presenting with cardiogenic shock or severe acute decompensated heart failure who require aortic or heart assist procedures. These studies focus on periprocedural hemodynamic stabilization, end-organ perfusion, and early survival, enrolling critically ill inpatient populations often with multiple comorbidities and high resource use. Results are highly relevant to clinicians and payers because device selection and timing drive ICU length of stay, complication rates, and immediate resource intensity that determine DRG payments and quality metrics.
Comparative effectiveness and procedural strategy studies in durable and temporary assist device implantation: observational registries and pragmatic trials comparing surgical versus percutaneous approaches, anticoagulation strategies, or escalation algorithms for patients receiving ventricular assist devices or other heart-assist implants during index hospitalization. These studies target heterogeneous inpatient cohorts ranging from elective support for advanced heart failure to urgent support in acute coronary syndromes, and they examine outcomes such as in-hospital complications, reoperation, transfusion, and discharge disposition. Findings inform clinician decision-making around procedure selection and perioperative management and help payers and hospital administrators optimize pathways that affect case mix index, resource allocation, and readmission risk under the DRG.
Post-discharge outcomes and cost-effectiveness studies: longitudinal cohort studies and health economics analyses following survivors of aortic and heart assist procedures to assess long-term functional status, device-related complications, rehospitalization rates, quality of life, and total cost of care over months to years. These investigations often enroll patients discharged after complex index stays captured by this DRG and stratify by discharge destination (home, skilled nursing facility) and need for durable support or transplant listing. Such evidence is important for providers and payers to plan post-acute care networks, anticipate downstream utilization that affects bundled payments, and develop interventions to reduce readmissions and improve value for this high-cost patient group.

Acute mechanical circulatory support device trials: randomized or prospective comparative studies evaluating short-term outcomes of different temporary left ventricular assist devices, extracorporeal membrane oxygenation (ECMO) strategies, or intra-aortic balloon alternatives in patients presenting with cardiogenic shock or severe acute decompensated heart failure who require aortic or heart assist procedures. These studies focus on periprocedural hemodynamic stabilization, end-organ perfusion, and early survival, enrolling critically ill inpatient populations often with multiple comorbidities and high resource use. Results are highly relevant to clinicians and payers because device selection and timing drive ICU length of stay, complication rates, and immediate resource intensity that determine DRG payments and quality metrics.
Comparative effectiveness and procedural strategy studies in durable and temporary assist device implantation: observational registries and pragmatic trials comparing surgical versus percutaneous approaches, anticoagulation strategies, or escalation algorithms for patients receiving ventricular assist devices or other heart-assist implants during index hospitalization. These studies target heterogeneous inpatient cohorts ranging from elective support for advanced heart failure to urgent support in acute coronary syndromes, and they examine outcomes such as in-hospital complications, reoperation, transfusion, and discharge disposition. Findings inform clinician decision-making around procedure selection and perioperative management and help payers and hospital administrators optimize pathways that affect case mix index, resource allocation, and readmission risk under the DRG.
Post-discharge outcomes and cost-effectiveness studies: longitudinal cohort studies and health economics analyses following survivors of aortic and heart assist procedures to assess long-term functional status, device-related complications, rehospitalization rates, quality of life, and total cost of care over months to years. These investigations often enroll patients discharged after complex index stays captured by this DRG and stratify by discharge destination (home, skilled nursing facility) and need for durable support or transplant listing. Such evidence is important for providers and payers to plan post-acute care networks, anticipate downstream utilization that affects bundled payments, and develop interventions to reduce readmissions and improve value for this high-cost patient group.

OpenPayer

Summary & Overview

Aortic and Heart Assist Procedures Except Pulsation Balloon with MCC: Inpatient Reimbursement Overview

DRG 268 Overview

Clinical Trials

Related Codes

Clinical Trials

Related Codes